AMS (American Medical Systems) closes TherMatrx deal:
This article was originally published in Clinica
American Medical Systems (AMS) has completed its acquisition of TherMatrx, the developer of TMx2000, an in-office treatment for benign prostatic hyperplasia. The technology was originally developed by BSD Medical, a Salt Lake City company with substantial holdings in TherMatrx. AMS of Minnetonka, Minnesota, first announced its intention to purchase TherMatrx, which includes all of BSD's holdings in the company, in June (see Clinica No 1113, p 13).
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.